Hope for schwannomatosis pain: new drug trial launches
NCT ID NCT05684692
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study tests two experimental drugs, siltuximab and erenumab, to see if they can safely reduce chronic pain in people with schwannomatosis, a condition that causes painful nerve tumors. About 40 adults with moderate-to-severe pain will receive either a drug or a placebo. The main goal is to measure changes in worst pain over 12 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAIN, CHRONIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital Cancer Center
RECRUITINGBoston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict chronic pain after breast cancer surgery?
- Teaching doctors to talk about pain: a new approach to safer opioid prescribing
- Can a silent word ease both PTSD and chronic pain? a VA trial puts mantram repetition to the test
- Smartphone app aims to decode chronic pain patterns
- New symptom diaries aim to improve daily tracking of recurrent UTIs, especially for seniors
- Online pain coping skills may ease joint pain in breast cancer survivors